1-20 of 33
Nizar Bahlis, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Nizar Bahlis, MD, Jeffrey A. Zonder, Susan Wroblewski, PhD, Ming Qi, MD PhD, Thomas Renaud, Carolyn Jackson, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1831.
https://doi.org/10.1182/blood-2019-123486
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1866.
https://doi.org/10.1182/blood-2019-123483
Published: 2019
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar Bahlis, MD, Thierry Facon, MD, Saad Z. Usmani, MD, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD, PhD, Cyrille Touzeau, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MBBS, FRACP, FRCPA, MD, Hartmut Goldschmidt, Michael E O'Dwyer, MD, Christopher P Venner, MD, Katja C. Weisel, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2019) 134 (Supplement_1): 1875.
https://doi.org/10.1182/blood-2019-123426
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Suzanne Lentzsch, MD PhD, Cristina Gasparetto, MD, Nizar Bahlis, MD, Christine I Chen, MD, Brea C. Lipe, MD, Gary J. Schiller, MD, Sascha A Tuchman, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, Natalie Scott Callander, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Muhamed Baljevic, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3165.
https://doi.org/10.1182/blood-2019-124370
Published: 2019
Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 686.
https://doi.org/10.1182/blood-2019-131981
Published: 2019
Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 572.
https://doi.org/10.1182/blood-2019-127593
Published: 2019
Journal Articles

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Nizar Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea C. Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J. Sutherland, MD PhD, William I. Bensinger, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Christopher P Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie Scott Callander, MD, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 141.
https://doi.org/10.1182/blood-2019-122907
Published: 2019
Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3121.
https://doi.org/10.1182/blood-2019-124457
Published: 2019
Journal Articles

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Cristina Gasparetto, MD, Gary J. Schiller, MD, Natalie Scott Callander, MD, Suzanne Lentzsch, MD PhD, Sascha A Tuchman, MD, Nizar Bahlis, MD, Darrell J White, MD, Christine I Chen, MD, Heather J. Sutherland, MD PhD, Muhamed Baljevic, MD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Brea C. Lipe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3157.
https://doi.org/10.1182/blood-2019-122902
Published: 2019
Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta
Journal: Blood
Blood (2019) 134 (Supplement_1): 1793.
https://doi.org/10.1182/blood-2019-126828
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 405.
https://doi.org/10.1182/blood-2018-99-113585
Published: 2018
Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3272.
https://doi.org/10.1182/blood-2018-99-113177
Published: 2018
Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, MD, Gustavo Fonseca, Donna Reece, Amit Agarwal, MD PhD, Weiyuan Chung, Faiza Zafar, MPAS, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3271.
https://doi.org/10.1182/blood-2018-99-111920
Published: 2018
Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

William E. Pierceall, Nizar Bahlis, MD, David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Shanti Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, Gustavo Fonseca, Donna Reece, Weiyuan Chung, Natalya Serbina, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2018-99-111554
Published: 2018
Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Cristina J Gasparetto, MD, Suzanne Lentzsch, MD, Gary J. Schiller, MD, William Bensinger, MD, Nizar Bahlis, MD, Heather J. Sutherland, MD PhD, Darrell J. White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Christine I Chen, MD, Aldo Del Col, Jatin J. Shah, MD, Jacqueline Jeha, Jean-Richard Saint-Martin, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Joel G. Turner, PhD, Daniel M Sullivan, MD, Brea Lipe, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 599.
https://doi.org/10.1182/blood-2018-99-117201
Published: 2018
Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 952.
https://doi.org/10.1182/blood-2018-99-113504
Published: 2018